sameAs
Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients.Unstimulated salivary flow, pH, proteins and oral health in patients with Juvenile Idiopathic ArthritisM-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patientsPlasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.Therapy of psoriasis with narrowband ultraviolet-B light influences plasma concentrations of MMP-2 and TIMP-2 in patients.Influence of narrowband ultraviolet-B phototherapy on plasma concentration of matrix metalloproteinase-12 in psoriatic patients.Plasma levels of IL-17, VEGF, and adrenomedullin and S-cone dysfunction of the retina in children and adolescents without signs of retinopathy and with varied duration of diabetes.Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients.The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curvePlasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patientsPlasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer PatientsPlasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients
P50
Q32173966-903205D2-515E-433F-BC80-F1786B1315B8Q33631646-4C89B77D-10B7-4805-AE50-D435B2BB3370Q33760034-A5DE4E25-410D-4CFB-A998-8F2759891EDDQ35589339-0A61538C-D1B5-4BE6-A438-EC7B41138FCCQ36631494-B5D7185A-8529-42D9-A3EB-AA8623FB66D0Q36636689-338BE9ED-7363-4F7A-8882-0E50F77D5F00Q37100214-56A047B4-3F47-42E4-BC37-6A591DA703BBQ41610884-4FA6ECD7-D254-4137-B8BA-5D8DD2D987CFQ41690217-67B0947E-EC6A-4395-9748-CC2AB471551FQ42844120-D7669B57-638B-422B-A73D-7B0381ABFF44Q48023907-527DC232-3280-45EE-9A68-B8462EFCCE5CQ51221041-653C06DD-4286-450E-B5E3-10C27D2BAE12Q51366910-94A54F01-FE1C-4BC4-9E94-FF0925F47D84Q57156716-08EB540B-DC10-4DA8-B934-42835A9E0693Q57179048-02EDF0C7-D557-416A-9B49-F673B49E1E75Q89210275-58E489C6-8B36-4B09-AAA0-EB58242A59FDQ91169853-8923BADC-6E55-40E9-8BB5-AA9164798336
P50
description
Polish researcher
@en
Pools lecturer
@nl
polnischer Lecturer
@de
polski naukowiec
@pl
profesor d'educación superior polacu
@ast
taighdeoir Polannach
@ga
name
Sławomir Ławicki
@ast
Sławomir Ławicki
@ca
Sławomir Ławicki
@de
Sławomir Ławicki
@en
Sławomir Ławicki
@es
Sławomir Ławicki
@fr
Sławomir Ławicki
@ga
Sławomir Ławicki
@gl
Sławomir Ławicki
@it
Sławomir Ławicki
@nl
type
label
Sławomir Ławicki
@ast
Sławomir Ławicki
@ca
Sławomir Ławicki
@de
Sławomir Ławicki
@en
Sławomir Ławicki
@es
Sławomir Ławicki
@fr
Sławomir Ławicki
@ga
Sławomir Ławicki
@gl
Sławomir Ławicki
@it
Sławomir Ławicki
@nl
altLabel
S Ławicki
@en
S Ławicki
@nl
Slawomir Lawicki
@en
prefLabel
Sławomir Ławicki
@ast
Sławomir Ławicki
@ca
Sławomir Ławicki
@de
Sławomir Ławicki
@en
Sławomir Ławicki
@es
Sławomir Ławicki
@fr
Sławomir Ławicki
@ga
Sławomir Ławicki
@gl
Sławomir Ławicki
@it
Sławomir Ławicki
@nl
P106
P1153
6602666166
P1412
P1559
Sławomir Ławicki
@pl
P21
P214
82152682579123312618
P27
P31
P3124
P496
0000-0001-6747-2123
P735
P7859
viaf-82152682579123312618